Recombinant Human CD36 protein(Gly30-Asn439), His-tagged

• Cat.No.: CD36-3184H
• Product Overview: Recombinant Human CD36 (NP_001001547.1)(Gly 30-Asn 439) was expressed in HEK293, fused with a polyhistidine tag at the C-terminus and a signal peptide at the N-terminus.

Specification

• Source: HEK293
• Species: Human
• Tag: His
• Protein length: Gly30-Asn439
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The secreted recombinant human CD36 comprises 421 amino acids with a predicted molecular mass of 48.1 kDa. As a result of glycosylation, the apparent molecular mass of rh CD36 is approximately 62.6 kDa in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: > 88 % as determined by SDS-PAGE. > 85 % as determined by SEC-HPLC.
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: CD36 CD36 molecule (thrombospondin receptor) [ Homo sapiens ]
• Official Symbol: CD36
• Synonyms: CD36; CD36 molecule (thrombospondin receptor); CD36 antigen (collagen type I receptor, thrombospondin receptor); platelet glycoprotein 4; FAT; GP3B; GP4; GPIV; SCARB3; GPIIIB; PAS IV; PAS-4 protein; glycoprotein IIIb; cluster determinant 36; fatty acid translocase; platelet glycoprotein IV; scavenger receptor class B, member 3; leukocyte differentiation antigen CD36; CHDS7; PASIV; BDPLT10
• Gene ID: 948
• mRNA Refseq: NM_000072
• Protein Refseq: NP_000063
• MIM: 173510
• UniProt ID: P16671

Case Study

Case 1: Gadagkar SG, et al. Sci Rep. 2023

In newborn brains, the innate immune response triggers strong microglial activation and TLRs induction, but how CD36 affects TLRs, especially TLR2 and TLR4, is unclear. We used a CD36-blocking antibody on 8-day-old mice and observed their response to LPS, an endotoxin. The blocking antibody reduced inflammation and TLR2/3 signaling without affecting the IRF3 pathway. Similarly, in human microglia, anti-CD36 lowered TLR2/3 levels but didn't impact TLR4 or IRF3, hinting at shared regulatory pathways between mice and humans. This suggests that CD36 plays a role in modulating neuroinflammation by altering immune responses.

Fig1. Western blot of total protein lysates from the control, anti-CD36, LPS and anti-CD36 + LPS injected mice.

Fig2. Western blot of total protein lysates of HMC3 cells treated with anti-CD36 antibody.

Case 2: Tao L, et al. Med Oncol. 2022

CD36, which manages fatty acid intake, shows promise for cancer treatment. This study explored its role in HCC progression using databases and lab tests on samples and cell lines. Results showed CD36 is upregulated in HCC, boosting cell proliferation and metastasis by enhancing fatty acid intake. Knocking down CD36 reduced these effects by suppressing AKR1C2, a gene linked to fatty acid regulation. Essentially, CD36 accelerates HCC by promoting AKR1C2 expression and increasing fatty acid consumption.

Fig1. The expression of CD36 in 5 clinical samples was detected by western blot.

Fig2. Western blot was used to detect the expression of CD36 in normal hepatocytes and HCC cell lines.

Application

CD36 is a crucial membrane glycoprotein that plays diverse roles in body and disease processes, such as how our bodies handle fats, respond to inflammation, take up lipids, and regulate immune functions. In scientific studies, recombinant CD36 helps us understand how it moves fatty acids around in places like fat tissue, muscles, and the intestines. It manages lipid levels and inflammation by joining with thrombospondin-1 (TSP-1). Meanwhile, in cardiovascular research, CD36's involvement in absorbing oxidized LDL is a part of how atherosclerosis develops. When it comes to cancer, particularly liver cancer, CD36 helps tumors by creating an environment that dampens immune responses. By blocking CD36, we can boost immune activity against tumors and improve the effects of immune checkpoint inhibitors. In diabetes and obesity research, CD36 influences fat absorption and insulin signaling, with inhibition improving fat metabolism and insulin sensitivity. It also affects obesity by regulating gut microbiota and fat absorption. In chronic kidney disease, CD36 expression increases, promoting disease progression through lipid deposition and oxidative stress, marking it as a potential biomarker. CD36 is also crucial in developing high-affinity antibodies for various detection methods, contributing significantly to research on metabolic, cardiovascular, and tumor conditions. Industrially, recombinant CD36 is expressed with high purity and low endotoxin levels for various applications, including developing diagnostic reagents to measure its disease expression levels. It plays a role in drug development targeting metabolic and immune regulation functions, offering therapeutic potential for obesity, diabetes, cardiovascular diseases, and cancer. As a fundamental research tool, it aids in understanding CD36's function in cell adhesion, signaling, and immune cell activity, showcasing its wide-ranging application in both research and industrial contexts, particularly in diseases related to metabolism, cardiovascular systems, cancer, and immune regulation.

Fig1. CD36 functions as both a signal transducer and fatty acid transporter. (Yiliang Chen, 2022)

Fig2. CD36 plays a role in tumor immunity. (Xinzhi Liao, 2022)